Theranostics

Scope & Guideline

Unlocking New Horizons in Pharmacology and Medicine.

Introduction

Explore the comprehensive scope of Theranostics through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Theranostics in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1838-7640
PublisherIVYSPRING INT PUBL
Support Open AccessYes
CountryAustralia
TypeJournal
Convergefrom 2012 to 2024
AbbreviationTHERANOSTICS / Theranostics
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA

Aims and Scopes

The journal 'Theranostics' focuses on the intersection of therapeutic and diagnostic strategies, emphasizing the development of personalized medicine and innovative technologies for disease management. It aims to bridge the gap between basic research and clinical application, fostering advancements in drug delivery systems, imaging techniques, and biomarker discovery.
  1. Theranostic Applications:
    The journal emphasizes the development and application of theranostic agents that simultaneously diagnose and treat diseases, particularly in oncology. This includes the use of nanoparticles, radioligands, and imaging agents that provide real-time monitoring of therapeutic responses.
  2. Nanomedicine and Drug Delivery:
    A significant focus is on nanotechnology and its applications in drug delivery systems. This encompasses the design of nanoparticles and nanocarriers that enhance the bioavailability and efficacy of therapeutics, especially for cancer treatment.
  3. Biomarkers and Personalized Medicine:
    The journal highlights the discovery and validation of biomarkers that can predict treatment responses and disease progression. This is crucial for the development of personalized therapeutic strategies tailored to individual patient profiles.
  4. Extracellular Vesicles and Cell Communication:
    Research on extracellular vesicles (EVs) is prominent, exploring their roles in intercellular communication, immune modulation, and as vehicles for drug delivery. EVs are studied for their potential in regenerative medicine and cancer therapy.
  5. Immunotherapy and Immune Modulation:
    The journal explores the mechanisms and applications of immunotherapy, focusing on strategies that enhance the immune response against tumors. This includes the development of immune checkpoint inhibitors and engineered immune cells.
  6. Advanced Imaging Techniques:
    Innovative imaging modalities, such as molecular imaging and ultrasound-guided techniques, are investigated for their role in enhancing the precision of diagnostics and monitoring therapeutic outcomes.
Recent trends in 'Theranostics' indicate a dynamic evolution of research themes, reflecting the growing integration of technology, personalized medicine, and innovative therapeutic strategies.
  1. Integration of Artificial Intelligence:
    The application of artificial intelligence (AI) in diagnostics and therapeutics is gaining traction, enabling more accurate predictions of treatment outcomes and improving the design of personalized therapies.
  2. Targeted and Combination Therapies:
    There is an increasing focus on targeted therapies that combine multiple modalities, such as immunotherapy with chemotherapy or radiotherapy, to enhance treatment efficacy and overcome resistance.
  3. Microbiome Research and Its Therapeutic Implications:
    Research exploring the gut microbiome's role in health and disease is emerging, particularly its influence on cancer therapy responses and overall patient outcomes.
  4. Regenerative Medicine and Stem Cell Applications:
    The use of stem cells and their derivatives for regenerative medicine is becoming a prominent theme, particularly in the context of tissue repair and treatment of degenerative diseases.
  5. Biomaterials and Smart Drug Delivery Systems:
    Innovative biomaterials designed for controlled and targeted drug delivery are trending, with a focus on enhancing therapeutic efficacy while minimizing side effects.
  6. Extracellular Vesicle Therapeutics:
    The therapeutic potential of extracellular vesicles, including their use as drug delivery vehicles and biomarkers, is rapidly expanding, indicating a shift towards utilizing natural cellular components for therapeutic applications.

Declining or Waning

While 'Theranostics' maintains a robust focus on emerging therapeutics and diagnostics, some themes have seen a decline in prominence over recent years, reflecting shifts in research priorities and technological advancements.
  1. Conventional Chemotherapy Approaches:
    There is a noticeable decline in publications centered on traditional chemotherapy methods without the integration of novel delivery systems or biomarkers. This shift suggests a move towards more targeted and personalized treatment modalities.
  2. Basic Laboratory Studies Without Clinical Relevance:
    Research that lacks direct implications for clinical application or translational potential is less frequently published, as the journal increasingly prioritizes studies that bridge laboratory findings with clinical outcomes.
  3. Non-targeted Drug Development:
    There is a waning interest in non-targeted approaches to drug development, as the field moves towards more precise and targeted therapies that consider individual patient characteristics and tumor heterogeneity.
  4. Non-immunotherapeutic Strategies:
    While immunotherapy continues to rise, publications focused solely on non-immunotherapeutic strategies without considering immune interactions or responses are becoming less common.

Similar Journals

IMMUNOLOGICAL INVESTIGATIONS

Elevating Immunological Knowledge for Professionals and Scholars
Publisher: TAYLOR & FRANCIS INCISSN: 0882-0139Frequency: 8 issues/year

IMMUNOLOGICAL INVESTIGATIONS, published by Taylor & Francis Inc, is a leading journal in the field of immunology and related medical sciences, with an established presence since 1972. With a focus on cutting-edge research and critical insights in immunological methods and theories, this journal serves as a pivotal platform for researchers, professionals, and students alike. Though it currently holds a Q3 ranking in Immunology and a Q2 ranking in miscellaneous medicine as of 2023, its Scopus rank of #129 out of 236 reflects its dedication to advancing the understanding of immune responses and therapies. The journal's commitment to rigorous peer review and high-quality publications enables it to remain relevant and influential in the ever-evolving landscape of immunological research. Subscription is required to access its extensive archive, which spans critical developments in the field of immunology from 1972 to 2024.

Advanced Therapeutics

Driving impactful research in advanced therapeutics.
Publisher: WILEYISSN: Frequency: 12 issues/year

Advanced Therapeutics, published by WILEY in the United Kingdom, stands at the forefront of medical and pharmaceutical research, offering invaluable insights from 2018 to 2024. This distinguished journal, with an E-ISSN of 2366-3987, is recognized for its exceptional academic rigor, boasting an impressive array of Q1 categorizations in essential fields such as Biochemistry (medical), Pharmaceutical Science, and Pharmacology. With its strategic focus on interdisciplinary studies and cutting-edge therapeutic developments, Advanced Therapeutics serves as a vital resource for researchers, professionals, and students keen on advancing their knowledge and contributing to the evolving landscape of medicine and genetics. The journal's high Scopus rankings further affirm its impact, with significant placements in multiple categories underscoring the quality of published research. Although the journal operates under a subscription model, its accessibility to high-impact findings ensures that it remains a pivotal platform for innovative discourse in therapeutics.

CYTOTECHNOLOGY

Cultivating Discovery: Inspiring New Horizons in Bioengineering and Biotechnology.
Publisher: SPRINGERISSN: 0920-9069Frequency: 6 issues/year

CYTOTECHNOLOGY, an esteemed journal published by Springer, stands as a vital resource in the fields of Bioengineering, Biomedical Engineering, and Biotechnology. With an impact factor reflective of its solid position within academia, this journal encompasses a broad scope dedicated to the advancement of cytotechnological research and applications from its inception in 1987 through to its latest volumes in 2024. Based in the Netherlands, it is committed to providing researchers, professionals, and students with high-quality, peer-reviewed articles that contribute to the understanding and innovations in cytotechnology. Although currently not open access, CYTOTECHNOLOGY has garnered a commendable reputation, holding Q3 rankings in multiple categories, indicating its relevance and influence within the scientific community. Researchers are encouraged to submit their cutting-edge findings to share insights that can spark further advancements in this dynamic field.

International Journal of Nanomedicine

Transforming research into revolutionary healthcare solutions.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1178-2013Frequency: 1 issue/year

International Journal of Nanomedicine, published by DOVE MEDICAL PRESS LTD, is a leading open access journal dedicated to advancing the field of nanomedicine and its applications in healthcare. Since its establishment in 2006, the journal has grown significantly, now encompassing a wide array of topics including bioengineering, biomaterials, biophysics, drug discovery, and pharmaceutical sciences, and is recognized in Q1 quartiles across major categories like *Nanoscience and Nanotechnology* and *Organic Chemistry*. The journal boasts an impressive standing within the Scopus rankings, with high percentiles across various related fields, making it an invaluable resource for researchers, professionals, and students seeking to stay informed on the latest innovations and developments in nanomedicine. With its commitment to fostering an accessible and collaborative academic environment, the International Journal of Nanomedicine serves as a vital platform for disseminating transformative research that impacts scientific practice and healthcare outcomes globally.

Biomedical Journal

Elevating Biomedical Science to New Heights
Publisher: ELSEVIERISSN: 2319-4170Frequency: 6 issues/year

The Biomedical Journal, published by ELSEVIER, serves as a premier platform for disseminating groundbreaking research in the field of medicine, specifically within the Q1 category of Medicine (Miscellaneous). With the ISSN 2319-4170 and E-ISSN 2320-2890, this Open Access journal has been committed to advancing biomedical science since its inception in 2002. With an impressive Scopus rank of #31 out of 636 in General Medicine and a notable placement in the 95th percentile, the journal provides valuable insights and rigorous studies that contribute significantly to the medical community. Based in the Netherlands at RADARWEG 29, 1043 NX AMSTERDAM, the journal is highly regarded for its timely and diverse range of articles, fostering collaboration and innovation amidst researchers, professionals, and students alike. The ongoing engagement in the journal's converged years from 2012 to 2024 underscores its commitment to keeping pace with the evolving landscape of biomedical research, making it an essential resource for those seeking to stay at the forefront of medical advancements.

HEMATOLOGICAL ONCOLOGY

Exploring Breakthroughs in Cancer and Blood Disorders
Publisher: WILEYISSN: 0278-0232Frequency: 4 issues/year

HEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.

Medecine Nucleaire-Imagerie Fonctionnelle et Metabolique

Transforming Knowledge in Functional and Metabolic Imaging.
Publisher: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIERISSN: 0928-1258Frequency: 6 issues/year

Medicine Nucleaire-Imagerie Fonctionnelle et Metabolique is a prominent journal published by Elsevier France-Editions Scientifiques Medicales Elsevier, dedicated to the specialized fields of nuclear medicine and functional imaging. With an ISSN of 0928-1258 and an E-ISSN of 1878-6820, this esteemed publication has been a crucial platform for the dissemination of research and developments in the discipline since its inception in 1993. Covering a wide array of topics within biophysics, radiological and ultrasound technology, and radiology, the journal currently holds a Q4 category ranking in these fields, reflecting its significance within the academic community. Although there are currently no open access options available for readers, the journal caters to a niche audience of researchers, professionals, and students who seek to enhance their understanding of metabolic imaging and its applications. The 2023 Scopus ranks indicate its position as an emerging source of knowledge in a competitive landscape, making it an important resource for the latest studies and innovations in nuclear medicine.

Asian Journal of Pharmaceutical Sciences

Fostering collaboration in cutting-edge pharmaceutical science.
Publisher: SHENYANG PHARMACEUTICAL UNIVISSN: 1818-0876Frequency: 6 issues/year

Asian Journal of Pharmaceutical Sciences is a prestigious open-access journal published by Shenyang Pharmaceutical University, dedicated to advancing research and developments in the field of pharmaceutical sciences. Since its inception in 2009, the journal has successfully converged a wealth of knowledge and innovation, demonstrating an impressive track record with its open access model adopted in 2013, ensuring global dissemination of crucial research findings. With an outstanding impact factor and consistently ranked in the Q1 category for both Pharmaceutical Science and Pharmacology in 2023, it ranks among the top journals in its field, as evidenced by its impressive Scopus rankings—4th out of 183 in Pharmaceutical Science and 10th out of 313 in Pharmacology, showcasing its high relevance and credibility (98th and 96th percentiles respectively). Researchers, professionals, and students can access a diverse array of articles that encompass groundbreaking studies, reviews, and reports, solidifying the journal's position as a vital resource for anyone engaged in pharmaceutical research. With its commitment to quality and accessibility, Asian Journal of Pharmaceutical Sciences plays an essential role in fostering innovation and collaboration within the global scientific community.

Biomolecules & Therapeutics

Pioneering Pharmacological Insights for Global Health
Publisher: KOREAN SOC APPLIED PHARMACOLOGYISSN: 1976-9148Frequency: 4 issues/year

Biomolecules & Therapeutics is a prominent journal published by the Korean Society of Applied Pharmacology, dedicated to advancing knowledge in the fields of Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With an ISSN of 1976-9148 and an E-ISSN of 2005-4483, this journal serves as a vital platform for researchers and professionals to disseminate their findings from 2008 through 2024. Ranking in the Q2 category across multiple relevant fields, including Pharmacology and Drug Discovery, and consistently placing in the 60th to 70th percentiles in Scopus rankings, Biomolecules & Therapeutics exemplifies a commitment to high-quality research and scientific integrity. Although it operates on a traditional access model, readers can be assured of the journal's rigorous peer-review process, ensuring that published articles contribute meaningfully to ongoing discourse in pharmacological and biochemical research. Located in Seoul, South Korea, the journal stands at the forefront of innovation in healthcare, making it an essential resource for academics, students, and industry professionals alike.

CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS

Transforming pharmaceutical science through critical reviews.
Publisher: BEGELL HOUSE INCISSN: 0743-4863Frequency: 6 issues/year

CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS is an esteemed academic journal published by BEGELL HOUSE INC, focusing on the innovative field of drug delivery systems and therapeutic carriers. With an ISSN of 0743-4863 and E-ISSN 2162-660X, this journal serves as a pivotal resource for researchers, professionals, and students engaged in pharmaceutical sciences and pharmacology. Spanning from 1984 to 2024, it has sustained its relevance in an evolving landscape, holding a commendable Q2 ranking in both Medicine (miscellaneous) and Pharmaceutical Science, as well as a Q3 ranking in Pharmacology for 2023. The journal is well-regarded for its critical and comprehensive reviews that enhance understanding and drive advancements in therapeutic applications. Access options are variable, providing insights into contemporary practices and innovations that shape drug delivery strategies. With a strong emphasis on interdisciplinary approaches, CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS not only fosters scholarly dialogue but also propels forward the critical field of therapeutic delivery, making it a valuable asset for anyone looking to deepen their knowledge and influence within this dynamic area of study.